Month: August 2022

NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) — NetworkNewsAudio – D-Wave Quantum Inc. (NYSE: QBTS) announces the availability of a broadcast titled, “Investing in Quantum Computing: What Every Investor Needs to Know.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/e1PTH As the world’s only annealing quantum computing company, and with annealing quantum computing best suited for optimization problems, D-Wave Quantum Inc. (NYSE: QBTS) is uniquely positioned to capture a significant portion of the total addressable market (TAM) for combinatorial optimization problems. In a world where 39% of enterprises have abandoned complex problems because of time and difficulty to solve limitations, D-Wave [delivers quantum-hybrid solutions to these complex problems...

Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approval GENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) — RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), and its collaboration partner, Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), today announced that the European Commission has granted orphan medicinal product designation in the EU to ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD). ACER-001 was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in the U.S. for MSUD in 2014. “Orphan designation by the European Commission is another important milestone for the ACER-001 program that provides further validation of the important role we believe...

ROSELAND, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, August 16, 2022, to discuss the company’s financial results for the second quarter ended June 30, 2022, as well as the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 197590. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2306/46391or on the Investor Relations section of the Company’s website at https://www.milestonescientific.com/investors. An...

Revenue for the first six months of 2022 rose to $1.1 million Silver Spring, MD, Aug. 12, 2022 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, announced results for the second quarter ending June 30, 2022. Second Quarter 2022 Financial HighlightsRevenue increased 35% to $0.5 million from the prior-year quarter and decreased by 9% from the first quarter of 2022. The slight revenue decline from the first quarter of 2022 resulted from a decrease in Digital Asset prices throughout the quarter, partially offset by an increase in Digital Asset production as a result of our expanded blockchain infrastructure. Revenue for the first six months of 2022 rose to $1.1 million compared to $0.5 million for the same period in 2021, nearly reaching 2021 full-year revenue of $1.2 million. Gross...

Resurgence of Travel Sees Surge in Demand of Airport Self-care Solutions and Amenities for PassengersXpresSpa at JFK Terminal 4 XpresSpa Re-Opening at JFK, Terminal 4 Gate B22.NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, announced the re-opening of one of its top-performing XpresSpa™ locations at John F. Kennedy (JFK) International Airport’s Terminal 4.   Located in Terminal 4 near Gate B22, the re-opened XpresSpa will meet the needs of a new era of post-pandemic travelers—health-conscious air passengers seeking more self-care solutions and amenities—by providing traditional wellness services, such as neck and back massage, as well as state-of-the-art solutions incorporating technology that gives therapeutic...

Positive interim results from registration-enabling study of cosibelimab in locally advanced cutaneous squamous cell carcinoma announced in June 2022 Successful completion of pre-BLA meetings in July 2022 Biologics license application (“BLA”) submission for both metastatic and locally advanced cutaneous squamous cell carcinoma on track for later this year WALTHAM, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2022, and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “Over the past few months, we have made substantial progress towards the regulatory submission for, and potential approval...